Lecanemab

  • 1 on aging of 14 trials, 2 with no results posted
  • 9 of 14 trials sponsored by its developers

Trials

1 on aging of 14

Approved

  • FDA Leqembi

    6 Jan 2023Dementia, mild cognitive impairment

  • EMA Leqembi

    15 Apr 2025Cognitive Dysfunction, Alzheimer Disease, Dementia, mild cognitive impairment, amyloid pathology

  • FDA Leqembi Iqlik

    29 Aug 2025Dementia, mild cognitive impairment

Repurposing

Every condition in trials

  • Early preclinical alzheimer disease

    Phase 3Active, not recruiting1 trial

Development

Companies
  • EisaiPhase 3early Alzheimer's disease

Trial sponsors

Latest

Nov 2025: 0Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 01 in 12 months